Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Other Operating Expenses (2019 - 2025)

Biodesix's Other Operating Expenses history spans 7 years, with the latest figure at $4.9 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 93.74% year-over-year to $4.9 million; the TTM value through Dec 2025 reached -$38.5 million, down 193.68%, while the annual FY2025 figure was $16.8 million, 6.42% up from the prior year.
  • Other Operating Expenses reached $4.9 million in Q4 2025 per BDSX's latest filing, up from -$23.4 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $78.0 million in Q4 2024 to a low of -$78.7 million in Q4 2023.
  • Average Other Operating Expenses over 5 years is -$1.0 million, with a median of $3.3 million recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 742.31% in 2021, then plummeted 2479.37% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $2.5 million in 2021, then surged by 32.61% to $3.3 million in 2022, then tumbled by 2479.37% to -$78.7 million in 2023, then surged by 199.13% to $78.0 million in 2024, then tumbled by 93.74% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Other Operating Expenses are $4.9 million (Q4 2025), -$23.4 million (Q3 2025), and -$23.8 million (Q2 2025).